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EXPLORING THE DERIVATION OF UTILITY
VALUES USING A DISCRETE-CHOICE
CONJOINT ANALYSIS METHOD—A COST-
UTILITY ANALYSIS OF GEMCITABINE PLUS
CISPLATIN FOR THE TREATMENT OF BLADDER
CANCER
Davey P1, Rajan N2
1M-TAG, Sydney, NSW, Australia; 2Eli Lilly Australia Pty Ltd,
Sydney, NSW, Australia
Gemcitabine plus cisplatin (GEM/cis) displays similar 
efﬁcacy to methotrexate, vinblastine, doxorubicin plus
cisplatin (MVAC) in the treatment of advanced bladder
cancer. The main advantage of GEM/cis over MVAC is
superior tolerability, as evidenced by a lower incidence of
severe adverse effects.
OBJECTIVE: To determine whether GEM/cis offers value
for money compared with MVAC. 
METHODS: Direct medical costs were calculated for
each treatment, based on resource utilisation data 
collected during a randomised phase III trial. Utility
values were determined to capture the quality of life
(QoL) differences between the two therapies. A novel
methodology, involving the use of discrete-choice con-
joint analysis, was employed to examine the value asso-
ciated with the toxicity proﬁle of GEM/cis compared with
MVAC. Attributes included in the analysis (alopecia,
weight improvement, mouth ulcers, thrombocytopenia,
febrile neutropenia and length of life) were obtained from
a survey of oncology nurses. Length of life was included
to allow the trade-off between length of life and side
effects to be determined. This approach enables discrete
utility values to be calculated for each attribute.
RESULTS: Survey responses indicated a preference for
GEM/cis treatment. The extra utility beneﬁt with
GEM/cis was 0.204, mostly derived from reduced risk 
of febrile neutropenia, mouth ulcers and alopecia. The
incremental cost per quality-adjusted life-year gained was
AUS$25,000 (US$50,000). This is within an acceptable
range for Australia. Sensitivity analyses indicated the
results were robust. Using these results, a cost-utility
analysis was conducted and submitted to the Australian
Pharmaceutical Beneﬁts Advisory Committee to assist in
deciding whether GEM/cis should receive public subsidy.
GEM/cis gained funding for the treatment of bladder
cancer.
CONCLUSIONS: GEM/cis offers comparable survival
with a superior toxicity proﬁle and QoL beneﬁt. The
study demonstrated that utility values can be derived
using a discrete-choice conjoint analysis approach.
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ARE THE FRAMINGHAM-RISK EQUATIONS
VALID FOR EUROPE?
Wendland G1, Lauterbach K2
1Cologne, NW, Germany; 2University of Cologne, Cologne,
Germany
OBJECTIVES: Framingham-risk equations to estimate
coronary heart disease risk (CHD-risk) are used through-
out Europe, assuming their validity and generalizability.
The objective of our analysis is to check its accuracy using
prevalence and mortality data for Germany and other
sources of information. 
METHODS: We constructed a Markov model following
an average cohort of 30 years old persons without CHD,
to investigate future prevalences and the percentage of
persons dying from CHD. With respect to these outcomes
average CHD incidence rates interact with quantities such
as general mortality rates, CHD-fatality rates and 
long-term prognosis of CHD cases. In the baseline model
average age- and gender-speciﬁc CHD incidence rates
were based on the current risk factor distribution 
in Germany (German Health Survey 1998) and the 
Framingham risk-equations of Anderson (1991). In the
alternative model incidence rates were calculated so that
future probabilities of dying from CHD match current
data from the Statistical Yearbook.
RESULTS: Transferring the Framingham risk equations
to Germany vastly overestimates other ﬁgures on 
prevalence and CHD-Mortality below the age of 60 years.
Average CHD-risks increase with age but at a lower rate
as compared to total mortality rates. In comparison to the
baseline model calculated incidence rates in the alterna-
tive model are generally more than 50% lower than in
the baseline model under the age of 60 for both males
and females and 46% lower for males and 25% lower for
females at the age of 70.
CONCLUSIONS: At least in Europe Framingham 
risk-equations have to be used with caution nowadays.
Apart from continental differences, Framingham risk-
equations do not yet reﬂect recent time trends in CHD-
risk, which cannot be attributed to changes in risk factors.
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HOSPITAL-SPECIFIC RELATIVE INTENSITY
SCORES FOR PHARMACEUTICAL SERVICES
Foster DA
Solucient, LLC, Ann Arbor, MI, USA
OBJECTIVES: To evaluate the variability of case-mix
adjusted, estimated costs for pharmaceutical services
across acute care hospitals in the U.S., and to develop a
metric to be used in differentiating hospitals with regard
to case-mix adjusted intensity of pharmaceutical services. 
METHODS: Solucient all-payer, inpatient data from
acute care hospitals were used to derive cost estimates for
inpatient pharmaceutical services. These data have been
extensively published. The Medicare Cost Reports were
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used to apply hospital- and revenue center-speciﬁc 
cost-to-charge ratios to estimate pharmaceutical costs
from charges at the discharge level. The Diagnosis-
Related Group (DRG) methodology was used to case-mix
adjust the results. Relative value units were derived from
the hospital speciﬁc cost estimates. After trimming at +/-
three standard deviations, cluster analyses methods were
applied to the hospitals to allocate each hospital into one
of four levels of pharmaceutical service intensity.
RESULTS: The data set included 959 acute care hospi-
tals, representing inpatient pharmacy cost information on
more than 6.9 million discharges. The time period was
federal ﬁscal year 2000. DRG 495, lung transplant, was
the most costly group, while the least costly group was
DRG 391, normal newborn. Of the 959 hospitals, 11
(1.15%) were excluded after trimming on intensity score.
The mean relative value score for the remaining 948 
hospitals was 2.77, with a range of 1.17 to 5.02. The
standard deviation was 0.59.
CONCLUSIONS: These results provide empirical 
evidence from a very large sample of hospitals that the
intensity of pharmaceutical interventions in acute care
hospitals in the U.S. exhibits considerable variability. A
four-fold difference was detected in intensity score
between the lowest intensity hospitals and the highest.
This DRG-adjusted difference was not due to differences
in case-mix across hospitals. Further research should 
be done to determine whether patient outcomes are 
associated with low versus high pharmaceutical service
intensity.
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DEVELOPING A QUALITY APPRAISAL
INSTRUMENT TO EVALUATE THE PEDIATRIC
HEALTH ECONOMICS LITERATURE
Ungar WJ1, Menon D2, Lee A1, Staﬁnski T2
1The Hospital for Sick Children Research Institute,Toronto,
ON, Canada; 2Institute of Health Economics, Edmonton, AB,
Canada
OBJECTIVES: The Pediatric Economic Database 
Evaluation (PEDE) Project features a database of 787
pediatric economic evaluations published between 1980
and 1999. A goal of the PEDE Project is to appraise the
quality of pediatric economic evaluations published over
this period. The objective of this research was to develop
a valid and reliable quality appraisal instrument applica-
ble to economic evaluations in the pediatric population. 
METHODS: A draft instrument was constructed from
published checklists and questionnaires. New questions
pertaining to the pediatric population were incorporated.
An expert panel reviewed the draft instrument and the
proposed scoring scheme for face and content validity. 
A revised version was pilot-tested by three independent
appraisers. After addressing discrepancies in scores, a
ﬁnal version was created and subjected to inter-rater and
test-retest reliability assessment.
RESULTS: The 57 items in the ﬁnal questionnaire were
mapped onto fourteen domains: economic evaluation,
comparators, target population, time horizon, perspec-
tive, costs and resource use, outcomes, quality of life,
analysis, discounting, incremental analysis, sensitivity
analysis, conﬂict of interest, and conclusions. Among the
57 items, 46 have response options that are scored from
0 to 1. Inter-rater reliability was 0.75 (95% CI 0.66–0.81)
and test-retest reliability was 0.92 (95% CI 0.71–0.98).
CONCLUSIONS: The Pediatric Quality Appraisal Ques-
tionnaire is a comprehensive instrument demonstrating
face and content validity and very good reliability for
application in the appraisal of pediatric economic evalu-
ations. The instrument is currently being used in a quality
appraisal of a random sample of 150 publications from
the PEDE database.
HEALTH POLICY—CONSUMER ADVERTISING
ISSUES
HP5
THE RELATIONSHIP OF DIRECT-TO-CONSUMER
ADVERTISING AND CLINICIAN BEHAVIORAL
INTENTIONS
Zachry III WM, Jackson TR
The University of Arizona,Tucson, AZ, USA
OBJECTIVE: To examine the relationship between the
exposure of a patient to direct-to-consumer advertising
(DTCA), and the likelihood of clinician behavioral inten-
tions to provide information and medications. 
METHODS: A randomized mail survey of Arizona
primary care physicians (n = 1080) and physician 
assistants (n = 704) was conducted. Questionnaires 
were created with a hypothetical patient scenario varying
according to the informational exposure of the patient (2
levels: DTCA or drug reference book). All other wording
in the hypothetical scenarios was controlled. Clinicians
were randomly assigned one form of the questionnaire.
Each form solicited responses to questions related to the
likelihood of respondent behavioral intentions (6-point
scale, 6 = very likely to 1 = very unlikely) when faced with
the hypothetical patient scenario.
RESULTS: The response rate for useable questionnaires
was 44% (40.5% physicians and 49.3% physician assis-
tants). No overall statistically signiﬁcant differences were
found between the early responders and late responders.
Also, no statistically signiﬁcant differences were found
between responders and non-responders based on the
metropolitan designations of their practice settings. 
Relative to clinicians who received the “drug reference
book” patient scenario, clinicians who received the
DTCA patient scenario were: more likely to become
annoyed with a patient for asking for more information
about medications (p = 0.003); less likely to answer the
patient’s questions (p = 0.028) or provide additional
written information (p = 0.007); more likely to attempt
to change the subject rather than discuss an advertised
